Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Amifostine Reduces RT-Related Dry Mouth in H&N Cancer

January 1, 1998
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

n ORLANDO-Amifostine (Ethyol) given prior to radiation therapy in head and neck cancer patients significantly reduced the incidence of radiation-induced grade 2 xerostomia. Mucositis was not a dose-limiting toxicity, and patients generally were able to receive their scheduled radiation doses without delays,

n ORLANDO—Amifostine (Ethyol) given prior to radiation therapy in head and neck cancer patients significantly reduced the incidence of radiation-induced grade 2 xerostomia. Mucositis was not a dose-limiting toxicity, and patients generally were able to receive their scheduled radiation doses without delays,

David Brizel, MD, said at the American Society for Therapeutic Radiation and Oncology (ASTRO) meeting.

“Xerostomia leads to secondary problems for patients, including difficulty in eating and speaking, and an increase in dental caries, loss of teeth, and oral infections, resulting in an overall pronounced decrease in quality of life,” said Dr. Brizel, of the Department of Radiation Oncol-ogy, Duke University Medical Center.

Xerostomia can occur intermittently with standard fractionation schemes, he said, and can be permanent with cumulative doses exceeding 50 Gy.

This multinational randomized phase III trial took place from Oct 1995 to Aug 1997. The poster presented at the meeting showed the results of data available on the first 234 eligible patients who had a minimum of 3 months’ follow-up.

All patients had histologically confirmed squamous cell carcinoma of the head and neck, with 75% or more of the parotid gland included in the radiation treatment field.

Patients were stratified according to treatment center, site of disease (oropharynx, nasopharynx, oral cavity, larynx, other); nodal status (N0 vs N4); and total

radiation dose—50 to 60 Gy for postoperative low-risk patients, 60 to 66 Gy for postoperative high-risk patients, and 66 to 70 Gy for those receiving definitive radiation therapy.

Arm I patients were given amifostine, 200 mg/m2 IV over 3 minutes, 15 to 30 minutes before each fraction (1.8 to 2.0 Gy/day for 30 to 35 fractions). Arm II patients received radiation therapy without pretreatment amifostine.

Rating Symptoms

Stimulated and unstimulated saliva samplings were taken at baseline and at 1, 5, 11, 17, and 23 months post-radiation therapy. Xerostomia was rated according to the RTOG Acute Morbidity Criteria on a scale of 0 to 4, with 0 being no change from baseline and 4 being acute salivary gland necrosis.

Patients self-assessed symptoms on a 10-point analog scale looking at dryness of mouth, difficulty in speaking or eating, the need for fluids and oral comfort aids, and soreness of mouth. On this scale, 0 represents the most severe symptoms and 10 is absence of symptoms.

At 3 months after radiation therapy, patients in the amifostine arm showed significant benefit in terms of lessened symptoms, Dr. Brizel said. The amifostine patients had a median score of 7 for dry mouth, difficulty speaking, and need for fluids and oral comfort aids, compared with a median score of 5 for those on radiation therapy alone for dry mouth and difficulty speaking, and 4.5 for the need for fluids and oral comfort aids.

At 6-month follow-up, there was no difference in locoregional tumor control between the two groups, suggesting that amifostine did not adversely affect treatment efficacy.

The low daily dose of amifostine was generally well tolerated. Only eight patients in the amifostine group discontinued treatment—three because of nausea and vomiting, one due to an allergic reaction, one with intercurrent illness, and three due to personal decision or noncompliance with the program. No new or cumulative toxicities were noted.

Dr. Brizel and his colleagues are currently doing a follow-up study to determine if pretreatment with amifostine reduces the incidence of late xerostomia in this setting. A further ongoing study is looking at the benefit of amifostine in patients receiving concurrent radioche-motherapy for head and neck cancer.

Articles in this issue

Interferon Improves Survival In CML: 10-Year Follow-up
Update on Breast Cancer Chemoprevention Trials
Topotecan Plus Cytarabine Promising in MDS
Update of Letrozole Pivotal Trials in Advanced Breast Cancer
Arguments Against Mammograms for Age 40-49 Refuted
Proton Beam Therapy Appears Safer than Prostatectomy, X-rays
Doxorubicin-Paclitaxel Combination Active in Metastatic Breast Cancer: ECOG Phase II Trial
RT Effective Palliation for Malignant Melanoma
Metastatic Breast Cancer Responds to Docetaxel, Doxorubicin, Cytoxan
Prevention of Breast Cancer Begins With Public Health Education on Risks
Amifostine Reduces RT-Related Dry Mouth in H&N Cancer
ACR Prepares ‘Appropriateness Guidelines’ for Radiologists’ Use
Lab Studies Suggest New Approaches to Treating Gliomas
Stem Cell Factor Mobilizer Increases Aphereses Yields
NABCO Resource Card on Breast Cancer Available
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
Related Content
Advertisement

The European Commission is going to review the CHMP recommendations for marketing authorization in the EU, Iceland, Liechtenstein, and Norway.

CHMP Recommends Expanded Approval for 2 Pembrolizumab Indications

Tim Cortese
September 19th 2025
Article

The agency has recommended approval for subcutaneous pembrolizumab in all previous solid tumor indications, and for pembrolizumab in recurrent HNSCC.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


Previously, in December 2024, CRB-701 was granted FTD by the FDA for relapsed/refractory metastatic cervical cancer.

FDA Grants Fast Track Designation to CRB-701 in Pretreated Recurrent HNSCC

Tim Cortese
September 17th 2025
Article

The next-generation ADC, CRB-701, demonstrated an emerging objective response rate of 57% in a subgroup of patients with HNSCC.


The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

DART Therapy Exhibits Greater Tolerability in Oropharyngeal SCC

Roman Fabbricatore
September 3rd 2025
Article

The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.


High levels of long-lasting, multifunctional HPV16-specific CD8-positive T cells induced by PDS0101 promoted durable patient survival.

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

Tim Cortese
August 25th 2025
Article

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with frontline recurrent or metastatic head and neck squamous cell carcinoma.


In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
August 15th 2025
Article

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.

Related Content
Advertisement

The European Commission is going to review the CHMP recommendations for marketing authorization in the EU, Iceland, Liechtenstein, and Norway.

CHMP Recommends Expanded Approval for 2 Pembrolizumab Indications

Tim Cortese
September 19th 2025
Article

The agency has recommended approval for subcutaneous pembrolizumab in all previous solid tumor indications, and for pembrolizumab in recurrent HNSCC.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


Previously, in December 2024, CRB-701 was granted FTD by the FDA for relapsed/refractory metastatic cervical cancer.

FDA Grants Fast Track Designation to CRB-701 in Pretreated Recurrent HNSCC

Tim Cortese
September 17th 2025
Article

The next-generation ADC, CRB-701, demonstrated an emerging objective response rate of 57% in a subgroup of patients with HNSCC.


The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

DART Therapy Exhibits Greater Tolerability in Oropharyngeal SCC

Roman Fabbricatore
September 3rd 2025
Article

The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.


High levels of long-lasting, multifunctional HPV16-specific CD8-positive T cells induced by PDS0101 promoted durable patient survival.

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

Tim Cortese
August 25th 2025
Article

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with frontline recurrent or metastatic head and neck squamous cell carcinoma.


In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
August 15th 2025
Article

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.